Antibody therapy of pediatric B-cell lymphoma

Friederike Meyer-Wentrup, Verena de Zwart, Marc Bierings

Onderzoeksoutput: Bijdrage aan tijdschriftKort overzichtpeer review

3 Citaten (Scopus)


B-cell lymphoma in children accounts for about 10% of all pediatric malignancies. Chemotherapy has been very successful leading to an over-all 5-year survival between 80 and 90% depending on lymphoma type and extent of disease. Therapeutic toxicity remains high calling for better targeted and thus less toxic therapies. Therapeutic antibodies have become a standard element of B-cell lymphoma therapy in adults. Clinical experience in pediatric lymphoma patients is still very limited. This review outlines the rationale for antibody treatment of B-cell lymphomas in children and describes potential target structures on B-cell lymphoma cells. It summarizes the clinical experience of antibody therapy of B-cell lymphoma in children and gives an outlook on new developments and challenges for antibody therapy of pediatric B-cell lymphoma.

Originele taal-2Engels
ArtikelnummerArticle 00068
TijdschriftFrontiers in Oncology
Volume3 APR
StatusGepubliceerd - 2013
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Antibody therapy of pediatric B-cell lymphoma'. Samen vormen ze een unieke vingerafdruk.

Citeer dit